Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease

Biologicals

Volumn 44, Issue 1, 2016, Pages 33-36

  Malíčková, Karin ^a   Ďuricová, Dana ^b,c   Bortlík, Martin ^b,c   Hind'oš, Miroslav ^a   Machková, Naděžda ^b   Hrubá, Veronika ^b   Lukáš, Martin ^b   Zima, Tomáš ^a   Lukáš, Milan ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b IBD centre   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Biosimilar; CT P13; Enzyme linked immunosorbent assay; Inflammatory bowel disease; Infliximab

Indexed keywords

INFLIXIMAB;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; INTERMETHOD COMPARISON; LIMIT OF DETECTION; MALE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; IMMUNOASSAY; INFLAMMATORY BOWEL DISEASES; PROCEDURES;

DRUG MONITORING; FEMALE; HUMANS; IMMUNOASSAY; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MALE;

EID: 84952639364     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2015.09.005     Document Type: Article

References (17)

1. Amiot A., Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Ther Adv Gastroenterol 2015, 8(2):66-82.
2. Danese S., Gomollon F. Governing board and operational board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013, 7(7):586-589.
3. Hlavaty T., Letkovsky J. Biosimilars in the therapy of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2014, 26(6):581-587.
4. Beck A., Reichert J.M. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs 2013, 5(5):621-623.
5. D'Haens G.R., Sartor R.B., Silverberg M.S., Petersson J., Rutgeerts P. Future directions in inflammatory bowel disease management. J Crohns Colitis 2014, 8(8):726-734.
6. Ebbers H.C. Biosimilars: in support of extrapolation of indications. J Crohns Colitis 2014, 8(5):431-435.
7. Feagan B.G., Choquette D., Ghosh S., Gladman D.D., Ho V., Meibohm B., et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals 2014, 42(4):177-183.
8. Gecse K.B., Khanna R., van den Brink G.R., Ponsioen C.Y., Löwenberg M., Jairath V., et al. Biosimilars in IBD: hope or expectation?. Gut 2013, 62(6):803-807.
9. Shion H., Chen W. Structural comparison of infliximab and a biosimilar via subunit analysis using the waters biopharmaceutical platform with UNIFI 2013, Waters Corporation Application Note.
10. Mowat C., Cole A., Windsor A., Ahmad T., Arnott I., Driscoll R., et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011, 60(5):571-607. IBD Section of the British Society of Gastroenterology.
11. Kang Y.S., Moon H.H., Lee S.E., Lim Y.J., Kang H.W. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci 2015, 60(4):951-956.
12. McKeage K. A review of CT-P13: an infliximab biosimilar. BioDrugs 2014, 28(3):313-321.
13. Braun J, Kudrin A. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases. Immunotherapy; 7(2):73-87.
14. ®. mAbs 2014, 1163-1177. Taylor & Francis.
15. D'Haens G.R., Panaccione R., Higgins P.D., Vermeire S., Gassull M., Chowers Y., et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. Am J Gastroenterol 2011, 106(2):199-212.
16. Vande Casteele N., Buurman D.J., Sturkenboom M.G., Kleibeuker J.H., Vermeire S., Rispens T., et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012, 36(8):765-771.
17. Hernández-Flórez D., Valor L., de la Torre I., Nieto J.C., Martínez-Estupiñán L., González C., et al. Comparison of two ELISA versions for infliximab serum levels in patients diagnosed with ankylosing spondylitis. Rheumatol Int 2015, 35(6):1021-1025.